{
    "$schema": "https://github.com/Open-Systems-Pharmacology/QualificationPlan/releases/download/v3.3/OSP_Qualification_Plan_Schema.json",
    "Projects": [
        {
            "Id": "Dapagliflozin",
            "Path": "../../Dapagliflozin-Model.json",
            "BuildingBlocks": [],
            "SimulationParameters": [
                {
                    "Project": "Dapagliflozin",
                    "Simulation": "PO SD 10 mg (perm)",
                    "Path": "Dapagliflozin|logP (veg.oil/water)",
                    "TargetSimulations": [
                        "IV 0.08 mg (perm)",
                        "PO MD 10 mg (perm)",
                        "PO MD 100 mg (perm)",
                        "PO MD 2.5 mg (perm)",
                        "PO MD 20 mg (perm)",
                        "PO MD 50 mg (perm)",
                        "PO SD 10 mg IC tablet (Chang 2015) (perm)",
                        "PO SD 100 mg (perm)",
                        "PO SD 2.5 mg (perm)",
                        "PO SD 20 mg (perm)",
                        "PO SD 250 mg (perm)",
                        "PO SD 250 mg fed (perm)",
                        "PO SD 5 mg (perm)",
                        "PO SD 5 mg IC tablet (Chang 2015) (perm)",
                        "PO SD 50 mg (perm)",
                        "PO SD 500 mg (perm)"
                    ]
                },
                {
                    "Project": "Dapagliflozin",
                    "Simulation": "PO SD 10 mg (perm)",
                    "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
                    "TargetSimulations": [
                        "IV 0.08 mg (perm)",
                        "PO MD 10 mg (perm)",
                        "PO MD 100 mg (perm)",
                        "PO MD 2.5 mg (perm)",
                        "PO MD 20 mg (perm)",
                        "PO MD 50 mg (perm)",
                        "PO SD 10 mg IC tablet (Chang 2015) (perm)",
                        "PO SD 100 mg (perm)",
                        "PO SD 2.5 mg (perm)",
                        "PO SD 20 mg (perm)",
                        "PO SD 250 mg (perm)",
                        "PO SD 250 mg fed (perm)",
                        "PO SD 5 mg (perm)",
                        "PO SD 5 mg IC tablet (Chang 2015) (perm)",
                        "PO SD 50 mg (perm)",
                        "PO SD 500 mg (perm)"
                    ]
                }
            ]
        }
    ],
    "ObservedDataSets": [],
    "Plots": {
        "AxesSettings": {
            "GOFMergedPlotsPredictedVsObserved": [
                {
                    "Type": "X",
                    "Dimension": "Concentration (mass)",
                    "Unit": "µg/l",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Type": "Y",
                    "Dimension": "Concentration (mass)",
                    "Unit": "µg/l",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "GOFMergedPlotsResidualsOverTime": [
                {
                    "Type": "X",
                    "Dimension": "Time",
                    "Unit": "h",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Linear"
                }
            ],
            "ComparisonTimeProfile": [
                {
                    "Type": "X",
                    "Dimension": "Time",
                    "Unit": "h",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Type": "Y",
                    "Dimension": "Concentration (mass)",
                    "Unit": "µg/l",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsPredictedVsObserved": [
                {
                    "Type": "X",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "DDIRatioPlotsResidualsVsObserved": [
                {
                    "Type": "X",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ],
            "PKRatioPlots": [
                {
                    "Type": "X",
                    "Dimension": "Age",
                    "Unit": "year(s)",
                    "GridLines": false,
                    "Scaling": "Linear"
                },
                {
                    "Type": "Y",
                    "Dimension": "Dimensionless",
                    "Unit": "",
                    "GridLines": false,
                    "Scaling": "Log"
                }
            ]
        },
        "PlotSettings": {
            "ChartWidth": 500,
            "ChartHeight": 400,
            "Fonts": {
                "AxisSize": 11,
                "LegendSize": 9,
                "OriginSize": 9,
                "FontFamilyName": "Arial",
                "WatermarkSize": 40
            }
        },
        "AllPlots": [
            {
                "Project": "Dapagliflozin",
                "Simulation": "IV 0.08 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 2.5 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 5 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 10 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 20 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 50 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 100 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 250 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 500 mg (perm)",
                "SectionReference": "model-building"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 5 mg IC tablet (Chang 2015) (perm)",
                "SectionReference": "model-verification"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 10 mg IC tablet (Chang 2015) (perm)",
                "SectionReference": "model-verification"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO SD 250 mg fed (perm)",
                "SectionReference": "model-verification"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO MD 2.5 mg (perm)",
                "SectionReference": "model-verification"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO MD 10 mg (perm)",
                "SectionReference": "model-verification"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO MD 20 mg (perm)",
                "SectionReference": "model-verification"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO MD 50 mg (perm)",
                "SectionReference": "model-verification"
            },
            {
                "Project": "Dapagliflozin",
                "Simulation": "PO MD 100 mg (perm)",
                "SectionReference": "model-verification"
            }
        ],
        "GOFMergedPlots": [
            {
                "Title": "Goodness of fit plot for concentration in plasma",
                "SectionReference": "diagnostics-plots",
                "PlotTypes": [
                    "predictedVsObserved",
                    "residualsOverTime"
                ],
                "Groups": [
                    {
                        "Caption": "IV (model building)",
                        "Symbol": "Triangle",
                        "OutputMappings": [
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "IV 0.08 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "PO SD fasted (model building)",
                        "Symbol": "Circle",
                        "OutputMappings": [
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 2.5 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
                                    "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
                                ],
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 5 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 10 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)",
                                    "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)",
                                    "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
                                    "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
                                    "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)",
                                    "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)",
                                    "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                                    "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                                    "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
                                ],
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 20 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)",
                                    "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                                    "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                                    "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)",
                                    "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)"
                                ],
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 50 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)",
                                    "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)",
                                    "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
                                    "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)"
                                ],
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 100 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": [
                                    "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
                                    "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
                                ],
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 250 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 500 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "PO SD fed",
                        "Symbol": "Square",
                        "OutputMappings": [
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 250 mg fed (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "PO MD",
                        "Symbol": "Diamond",
                        "OutputMappings": [
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO MD 2.5 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO MD 10 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO MD 20 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO MD 50 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO MD 100 mg (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
                                "Color": "#000000"
                            }
                        ]
                    },
                    {
                        "Caption": "PO SD IC tablets (Chang 2015)",
                        "Symbol": "Asterisk",
                        "OutputMappings": [
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 5 mg IC tablet (Chang 2015) (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)",
                                "Color": "#000000"
                            },
                            {
                                "Project": "Dapagliflozin",
                                "Simulation": "PO SD 10 mg IC tablet (Chang 2015) (perm)",
                                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                                "ObservedData": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)",
                                "Color": "#000000"
                            }
                        ]
                    }
                ]
            }
        ],
        "ComparisonTimeProfilePlots": [
            {
                "Title": "Multiple Dose Escalation Study (day 1)",
                "SectionReference": "ct-profiles-overview",
                "SimulationDuration": 24,
                "TimeUnit": "h",
                "OutputMappings": [
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 2.5 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
                        "Caption": "2.5 mg",
                        "Color": "#FF0000",
                        "Symbol": "Triangle",
                        "StartTime": 0,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 10 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                        "Caption": "10 mg",
                        "Color": "#FF0000",
                        "Symbol": "Circle",
                        "StartTime": 0,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 20 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                        "Caption": "20 mg",
                        "Color": "#FF0000",
                        "Symbol": "Cross",
                        "StartTime": 0,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 50 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
                        "Caption": "50 mg",
                        "Color": "#FF0000",
                        "Symbol": "Diamond",
                        "StartTime": 0,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 100 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
                        "Caption": "100 mg",
                        "Color": "#FF0000",
                        "Symbol": "Square",
                        "StartTime": 0,
                        "TimeUnit": "h"
                    }
                ]
            },
            {
                "Title": "Multiple Dose Escalation Study (day 7)",
                "SectionReference": "ct-profiles-overview",
                "SimulationDuration": 24,
                "TimeUnit": "h",
                "OutputMappings": [
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 2.5 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
                        "Caption": "2.5 mg",
                        "Color": "#FF0000",
                        "Symbol": "Triangle",
                        "StartTime": 144,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 10 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                        "Caption": "10 mg",
                        "Color": "#FF0000",
                        "Symbol": "Circle",
                        "StartTime": 144,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 20 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                        "Caption": "20 mg",
                        "Color": "#FF0000",
                        "Symbol": "Cross",
                        "StartTime": 144,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 50 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
                        "Caption": "50 mg",
                        "Color": "#FF0000",
                        "Symbol": "Diamond",
                        "StartTime": 144,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 100 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
                        "Caption": "100 mg",
                        "Color": "#FF0000",
                        "Symbol": "Square",
                        "StartTime": 144,
                        "TimeUnit": "h"
                    }
                ]
            },
            {
                "Title": "Multiple Dose Escalation Study (day 14)",
                "SectionReference": "ct-profiles-overview",
                "SimulationDuration": 24,
                "TimeUnit": "h",
                "OutputMappings": [
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 2.5 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
                        "Caption": "2.5 mg",
                        "Color": "#FF0000",
                        "Symbol": "Triangle",
                        "StartTime": 312,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 10 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                        "Caption": "10 mg",
                        "Color": "#FF0000",
                        "Symbol": "Circle",
                        "StartTime": 312,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 20 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                        "Caption": "20 mg",
                        "Color": "#FF0000",
                        "Symbol": "Cross",
                        "StartTime": 312,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 50 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
                        "Caption": "50 mg",
                        "Color": "#FF0000",
                        "Symbol": "Diamond",
                        "StartTime": 312,
                        "TimeUnit": "h"
                    },
                    {
                        "Project": "Dapagliflozin",
                        "Simulation": "PO MD 100 mg (perm)",
                        "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                        "ObservedData": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
                        "Caption": "100 mg",
                        "Color": "#FF0000",
                        "Symbol": "Square",
                        "StartTime": 312,
                        "TimeUnit": "h"
                    }
                ]
            }
        ],
        "DDIRatioPlots": [],
        "PKRatioPlots": []
    },
    "Inputs": [
        {
            "Project": "Dapagliflozin",
            "Name": "Dapagliflozin",
            "Type": "Compound",
            "SectionReference": "final-input-parameters"
        },
        {
            "Name": "IC tablet (Chang 2015)",
            "Project": "Dapagliflozin",
            "Type": "Formulation",
            "SectionReference": "final-input-parameters"
        },
        {
            "Name": "Dissolved",
            "Project": "Dapagliflozin",
            "Type": "Formulation",
            "SectionReference": "final-input-parameters"
        }
    ],
    "Sections": [
        {
            "Reference": "introduction",
            "Title": "Introduction",
            "Content": "Content/Section1_Introduction.md"
        },
        {
            "Reference": "methods",
            "Title": "Methods",
            "Content": "Content/Section2_Methods.md",
            "Sections": [
                {
                    "Reference": "modeling-strategy",
                    "Title": "Modeling Strategy",
                    "Content": "Content/Section2.1_Modeling_Strategy.md"
                },
                {
                    "Reference": "data",
                    "Title": "Data",
                    "Content": "Content/Section2.2_Data.md"
                },
                {
                    "Reference": "model-parameters-and-assumptions",
                    "Title": "Model Parameters and Assumptions",
                    "Content": "Content/Section2.3_Model_Parameters_and_Assumptions.md"
                }
            ]
        },
        {
            "Reference": "results-and-discussion",
            "Title": "Results and Discussion",
            "Content": "Content/Section3_Results_and_Discussion.md",
            "Sections": [
                {
                    "Reference": "final-input-parameters",
                    "Title": "Final input parameters",
                    "Content": "Content/Input_table.md"
                },
                {
                    "Reference": "diagnostics-plots",
                    "Title": "Diagnostics Plots",
                    "Content": "Content/GOF_diagnostics.md"
                },
                {
                    "Reference": "ct-profiles",
                    "Title": "Concentration-Time Profiles",
                    "Content": "Content/Concentration_time_profiles.md",
                    "Sections": [
                        {
                            "Reference": "model-building",
                            "Title": "Model Building",
                            "Content": "Content/Concentration_time_profiles_building.md"
                        },
                        {
                            "Reference": "model-verification",
                            "Title": "Model Verification",
                            "Content": "Content/Concentration_time_profiles_verification.md"
                        },
                        {
                            "Reference": "ct-profiles-overview",
                            "Title": "Overview",
                            "Content": "Content/Concentration_time_profiles_overview.md"
                        }
                    ]
                }
            ]
        },
        {
            "Reference": "conclusion",
            "Title": "Conclusion",
            "Content": "Content/Section4_Conclusion.md"
        },
        {
            "Reference": "main-references",
            "Title": "References",
            "Content": "Content/References.md"
        }
    ],
    "Intro": [
        {
            "Path": "Content/titlepage.md"
        }
    ]
}